[1]
Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Physiopathological premises to nuclear medicine imaging and therapy of pancreatic neuroendocrine tumours. Curr. Radiopharm., 2019, 12, 98-106.
[2]
Briganti, V.; Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Gamma emitters in pancreatic endocrine tumors imaging in the PET era: Is there a clinical space for 99mTc-peptides? Curr. Radiopharm., 2019, 12, 156-170.
[3]
Carollo, A.; Papi, S.; Grana, C.M.; Chinol, M. State of the art and recent developments of radiopharmaceuticals for pancreatic neuroendocrine tumors imaging. Curr. Radiopharm., 2019, 12, 107-125.
[4]
Alsadik, S.; Yusuf, S.; Al-Nahhas, A. Peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours. Curr. Radiopharm., 2019, 12, 126-134.
[5]
Zamir, M.A.; Hakim, W.; Yusuf, S.; Thomas, R. Imaging of pancreatic-neuroendocrine tumours: An outline of conventional radiological techniques. Curr. Radiopharm., 2019, 12, 135-155.
[6]
Giovacchini, G.; Giovannini, E.; Riondato, M.; Ciarmiello, A. PET/MR tomographs: A review with technical.; Radiochemical and clinical perspectives. Curr. Radiopharm., 2017, 10, 184-194.
[7]
Mapelli, P.; Piccho, M. PET/MRI in neuroendocrine tumours: Blessings and curses. Curr. Radiopharm., 2019, 12, 96-97.
[8]
Werner, R.A.; Solnes, L.B.; Javadi, M.S.; Weich, A.; Gorin, M.A.; Pienta, K.J.; Higuchi, T.; Buck, A.K.; Pomper, M.G.; Rowe, S.P.; Lapa, C. SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: A proposed standardization framework. J. Nucl. Med., 2018, 59, 1085-1091.
[9]
Antoch, G.; Vogt, F.M.; Freudenberg, L.S.; Nazaradeh, F.; Goehde, S.C.; Barkhausen, J. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama, 2003, 290, 3199-3206.
[10]
Donati, O.F.; Reiner, C.S.; Hany, T.F.; Fornaro, J.; von Schulthess, G.K. Marincek. B.; Weishaupt, D. 18F-FDG-PET and MRI in patients with malignancies of the liver and pancreas. Accuracy of retrospective multimodality image registration by using the CT-component of PET/CT. Nuklearmedizin, 2010, 49, 106-114.
[11]
Samarin, A.; Burger, C.; Wollenweber, S.D.; Crook, D.W.; Burger, I.A.; Schmid, D.T.; von Schulthess, G.K.; Kuhn, F.P. PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 1154-1160.
[12]
Bodei, L.; Kidd, M.; Modlin, I.M.; Severi, S.; Drozdov, I.; Nicolini, S.; Kwekkeboom, D.J.; Krenning, E.P.; Baum, R.P.; Paganelli, G. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43, 839-851.
[13]
Bodei, L.; Sundin, A.; Kidd, M.; Prasad, V.; Modlin, I.M. The status of neuroendocrine tumor imaging: From darkness to light? Neuroendocrinology, 2015, 101, 1-17.
Download PDF Flyer